Systems and Computational Biomedicine · Weill Cornell Medicine
The Meydan Lab combines multiomics, machine learning, and statistical modeling to study gene regulation, lymphoma biology, and human physiology. Research spans chromatin and 3D genome organization, spatial tissue biology, and inflammatory and metabolic responses.
The lab studies how genetic and epigenetic alterations shape B-cell identity and lymphoma biology. Integrative analyses connect chromatin remodeling, transcriptional regulation, and 3D genome organization with malignant cell states and therapeutic vulnerabilities.
The lab develops machine-learning and statistical approaches for integrating molecular data and modeling biological variation. Methodological research addresses model interpretation, uncertainty, and generalization across studies.
Spatial transcriptomics, protein measurements, and single-cell profiles reveal the organization of lymphoma tissues. The lab develops integrative analyses of tumor heterogeneity, immune and stromal neighborhoods, and relationships between molecular alterations and tissue structure.
The lab studies inflammatory and metabolic responses through host proteomics and multiomic profiling. Research spans physiological stress, spaceflight, and host–microbiome interactions.
Studies of BAF disruption connected chromatin remodeling with altered CTCF binding, 3D genome organization, and lymphoma cell identity. Dr. Meydan led computational analyses and supervised contributing researchers in the 2026 Nature study. He shares first and corresponding authorship on that paper. He also shares first authorship on the 2024 ARID1A study and is a named inventor on its related patent application.
The NASA Twins Study provided the first integrated biomolecular view of the human response to spaceflight. Subsequent work identified mitochondrial stress as a central response and helped establish SOMA’s shared atlas and astronaut biobank. Dr. Meydan shares first authorship on the Twins and mitochondrial-stress studies and corresponding authorship on SOMA. His contributions span integrative analysis, methods, and research resources.
Acute myeloid leukemia (AML) is an aggressive cancer of the blood and bone marrow. In some patients, mutations in the IDH2 gene disturb DNA methylation and block blood-cell maturation. Preclinical studies showed that targeted inhibition of mutant IDH2 reversed these changes and restored differentiation in leukemia models. The work was cited in the clinical development of the IDH2 inhibitor enasidenib, approved by the FDA in 2017. Dr. Meydan contributed methods and epigenomic analysis and shares first authorship on the 2017 study.
During New York’s first COVID-19 wave, this research combined rapid RT-LAMP testing, viral genome sequencing, host-response profiling of nasopharyngeal swabs, autopsy and spatial tissue studies, and analyses of electronic health records. The RT-LAMP validation contributed to Color’s FDA emergency authorization in May 2020, when fully at-home self-testing was not yet available in the United States. Dr. Meydan shares first authorship on the Nature Communications study and corresponding authorship on the Cell Reports Medicine study of tissue damage.
All publications → Google Scholar → Portals, code and data →
Newspapers, magazines, broadcasters and space agencies have covered studies coauthored by Dr. Meydan. Selected coverage:
SWI/SNF & 3D genomeWeill Cornell MedicineA Unifying Mechanism for Cancer-Driving Mutations
SOMA / Inspiration4The New York TimesFour Astronauts Spent 3 Days in Space. Here's What It Did to Their Bodies.
SOMA / Inspiration4ScienceAstronauts face health risks—even on short trips in space
NASA Twins StudyCNNHuman health can be 'mostly sustained' for a year in space, NASA Twins Study finds
Principal Investigator, Meydan Lab
Systems and Computational Biomedicine
Weill Cornell Medicine
Dr. Meydan is a computational biologist at Weill Cornell Medicine. His research connects lymphoma genomics and chromatin regulation with spatial and single-cell biology. He develops computational approaches for molecular data integration and models of biological variation. His work also examines inflammatory and metabolic responses, host proteomics, and molecular adaptation to spaceflight.
Dr. Meydan joined Onegevity as a founding employee and built its GutBio microbiome product and analytical platform. He continued research leadership at Thorne HealthTech and is a co-founder of ARQ.
A joint position with the Barisic lab at Weill Cornell Medicine.
The Meydan Lab welcomes collaborations in cancer genomics, chromatin regulation, spatial biology, and computational method development. Please send a brief research question and a description of the available data to cem2009@med.cornell.edu.
Get in touch
